SCHEMBL1628909

SCHEMBL1628909

Cc1cc(=O)c(C(N)=O)c[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.42
ALDH1A1 P00352 2/20 0.40
ATM Q13315 1/20 0.40
BRD4 O60885 2/20 0.36
HMBS P08397 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CDC7 O00311 1/20 0.34
MAP2K2 P36507 1/20 0.34
MAP2K1 Q02750 1/20 0.34
NNMT P40261 2/20 0.33
SIRT3 Q9NTG7 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
BRPF1 P55201 1/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1146029 0.81 NOTUM (0.54) NOTUMALDH1A1KDM4EHSD17B10PIM3
Hydrochloric Acid SCHEMBL1626862 0.79 NOTUM (0.52) NOTUMALDH1A1KDM4EHSD17B10PIM3
SCHEMBL28341820 0.79 CCNC (0.44) ALDH1A1ATML3MBTL1MAP2K2MAP2K1
SCHEMBL23771966 0.77 DAO (0.40) ALDH1A1ATMBRD4L3MBTL1CDC7
SCHEMBL1627128 0.76 NR4A2 (0.50) NOTUMALDH1A1KDM4EHSD17B10MAP2K1
SCHEMBL26240985 0.73 MAP2K2 (0.42) NOTUMALDH1A1ATMBRD4L3MBTL1
SCHEMBL15333212 0.73 KMT2A (0.53) ALDH1A1ATML3MBTL1KDM4EHSD17B10
SCHEMBL16168454 0.71
SCHEMBL16918372 0.69 DAO (0.53) ALDH1A1ATMBRD4HMBSL3MBTL1
SCHEMBL2116156 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-62249970-A None JP disclosed
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2025-07-03 US disclosed
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 US disclosed
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2022-08-11 US disclosed
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 US disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 US disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 US disclosed
EP-2146779-B1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2016-08-10 EP disclosed
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2016-05-12 US disclosed
US-8440822-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. 2013-05-14 US disclosed
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER, INC. 2013-01-03 US disclosed
US-8247411-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2012-08-21 US disclosed
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-07-07 US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 US disclosed
CN-101678215-A Sulfonamide derivatives for the treatment of abnormal cell growth PFIZER PROD INC 2010-03-24 CN disclosed
EP-2146779-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2010-01-27 EP disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 US disclosed
WO-2008129380-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2008-10-30 WO disclosed
JP-S62249970-A PRODUCTION OF PYRIDONE-3-CARBOXAMIDE COMPOUND DAICEL CHEM IND LTD 1987-10-30 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NOTUM 2931/4885ALDH1A1 1427/4885ATM 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.